HOME >> MEDICINE >> NEWS
New awards, expanded focus for Pediatric AIDS Clinical Trials Group

The National Institute of Allergy and Infectious Diseases (NIAID) today announced $36 million in renewed funding for the Pediatric AIDS Clinical Trials Group (PACTG), and a greater focus on both adolescent research and international pediatric research. The new five-year awards will support 18 university-based clinical trials sites, a statistical and data management center, and a coordinating and operations center.

The PACTG has pioneered key trials evaluating treatments for children with HIV and has made great advances in reducing the rate of mother-to-infant HIV transmission in the developed world. The epidemic among adolescents in the United States, however, has become an increasing concern. The Centers for Disease Control and Prevention reports that 4,219 cumulative cases of AIDS among adolescents, or children ages 13 through 19, were reported through June 2001,(1) and the number of adolescents living with HIV is estimated to be much higher.

Because the average length of time between HIV infection and the development of AIDS is 10 years, it is believed that many adults became infected as adolescents. Most adolescents infected with HIV are at an early stage of disease and are ideal candidates for early intervention and treatment strategies.

HIV and AIDS also continue to take a devastating toll on women and children in developing countries, where more than 90 percent of all HIV/AIDS cases occur. In 2001, approximately 2.7 million children younger than age 15 were living with HIV/AIDS worldwide, and 580,000 children in this age group died from HIV-associated illnesses or AIDS, according to a UNAIDS report.(2) In addition to the suffering of children, 48 percent of adults living with HIV/AIDS in the world are women, many of whom are of childbearing age.(2) To this end, the PACTG will also directly support clinical research at four international sites, two in South Africa and two in Thailand.

"The Pediatric AIDS Clinical Trials
'"/>

Contact: Diana K. Carroll
dcarroll@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
7-Mar-2002


Page: 1 2 3 4 5

Related medicine news :

1. Routine HIV screening should be expanded, study finds
2. Partnership for Prevention and ACPM commend expanded coverage of preventive services under Medicare
3. Study of energy and health in Africa focuses spotlight on charcoal and forest management
4. Protecting human subjects focus of national FDA conference at UH
5. Non-lethal weapons focus of research study
6. Insulin resistance intervention after stroke focus of $33 million grant
7. Ethics of neuroimaging research to be focus of NIH/Stanford meeting
8. TIGER Workshop puts focus on space for African water management
9. UCI launches nations first medical education program focused on Latino culture
10. New initiative to focus on growing problem of cardiovascular disease in diabetics
11. Apraxia of speech in children is focus of new OHSU grant

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New awards expanded focus for Pediatric AIDS Clinical Trials Group

(Date:3/5/2015)... Southlake, TX (PRWEB) March 05, 2015 ... an in-office, non-surgical treatment for OB-GYNs and Urogynecologists. ... system, used for non-surgical dermatological application in aesthetics ... pleased to have a non-invasive, in-office procedure, and ... for women who want results without surgery. ThermiVa ...
(Date:3/5/2015)... Building on its commitment to provide ... The Academy of Oncology Nurse & Patient Navigators (AONN+) ... voice ™ (CONQUER ™). , “Cancer has ... and their loved ones each year,” says Pam Rattananont ... ever, there is a need in the oncology space ...
(Date:3/4/2015)... MyCpapStore.com, an online provider of CPAP equipment ... quality products designed to remedy the problem of snoring. ... merchandise from name-brand manufacturers, giving its customers access to ... Sleep apnea is a common condition affecting people of ... restricted airflow. The CPAP (continuous positive airway pressure) machine ...
(Date:3/4/2015)... Vegas, NV (PRWEB) March 04, 2015 In ... as the fight that is the main event. For ... and that fight will be for the UFC Featherweight Championship. ... the brash, often out-spoken native of Ireland, Conor “Notorious” McGregor. ... MGM Grand Garden Arena in Las Vegas, NV. , When ...
(Date:3/4/2015)... Dr. Christopher Asandra, M.D., Founder and Chief ... lamented the FDA’s recent decision to issue a ... that FDA’s conclusions are not supported by science, and ... testosterone deficiency. , “The FDA appears to have developed ... said Dr. Asandra. “There is not nearly enough evidence ...
Breaking Medicine News(10 mins):Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 2Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 3Health News:The Academy of Oncology Nurse & Patient Navigators Launches CONQUER: the patient voice™ to Help Meet the Informational Needs of Patients with Cancer 2Health News:Sleep Apnea Machines CPAP and BiPap Machines Now Available for Sale 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... Texas , March 4, 2015 ... II pilot study in patients with moderate to ... Dermatology. The open-label Phase II trial evaluated the ... monoclonal antibody that targets interleukin-1 alpha (IL-1a). IL-1a ... inflammatory cells present in skin lesions. The Company ...
(Date:3/4/2015)... Pa. , March 4, 2015  Results of ... 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin ... poster session at the 32 nd Annual Miami ... study, conducted by Moshe Papa , MD, FACS, ... at Tel Aviv University, reports an analysis of MarginProbe,s ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
Cached News: